Clinical Trial

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-29.
Trial Details
NCT Number NCT06532344
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Metastatic Pancreatic Cancer
Enrollment 32 participants
Start Date 2021-07-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-14